Ocular inflammatory events following COVID-19 vaccination : a multinational case series
© 2021. The Author(s)..
BACKGROUND: Inflammatory adverse events following COVID-19 vaccination are being reported amidst the growing concerns regarding vaccine's immunogenicity and safety, especially in patients with pre-existing inflammatory conditions.
METHODS: Multinational case series of patients diagnosed with an ocular inflammatory event within 14 days following COVID-19 vaccination collected from 40 centres over a 3 month period in 2021.
RESULTS: Seventy patients presented with ocular inflammatory events within 14 days following COVID-19 vaccination. The mean age was 51 years (range, 19-84 years). The most common events were anterior uveitis (n = 41, 58.6%), followed by posterior uveitis (n = 9, 12.9%) and scleritis (n = 7, 10.0%). The mean time to event was 5 days and 6 days (range, 1-14 days) after the first and second dose of vaccine, respectively. Among all patients, 36 (54.1%) had a previous history of ocular inflammatory event. Most patients (n = 48, 68.6%) were managed with topical corticosteroids. Final vision was not affected in 65 (92.9%), whereas 2 (2.9%) and 3 (4.3%) had reduction in visual acuity reduced by ≤3 lines and > 3 lines, respectively. Reported complications included nummular corneal lesions (n = 1, 1.4%), cystoid macular oedema (n = 2, 2.9%) and macular scarring (n = 2, 2.9%).
CONCLUSION: Ocular inflammatory events may occur after COVID-19 vaccination. The findings are based on a temporal association that does not prove causality. Even in the possibility of a causal association, most of the events were mild and had a good visual outcome.
| Errataetall: |
CommentIn: Graefes Arch Clin Exp Ophthalmol. 2023 Mar;261(3):897-899. - PMID 36280611 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Journal of ophthalmic inflammation and infection - 12(2022), 1 vom: 04. Jan., Seite 4 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Testi, Ilaria [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 04.09.2023 published: Electronic CommentIn: Graefes Arch Clin Exp Ophthalmol. 2023 Mar;261(3):897-899. - PMID 36280611 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1186/s12348-021-00275-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33517731X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33517731X | ||
| 003 | DE-627 | ||
| 005 | 20231225225250.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12348-021-00275-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1117.xml |
| 035 | |a (DE-627)NLM33517731X | ||
| 035 | |a (NLM)34982290 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Testi, Ilaria |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ocular inflammatory events following COVID-19 vaccination |b a multinational case series |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 04.09.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a CommentIn: Graefes Arch Clin Exp Ophthalmol. 2023 Mar;261(3):897-899. - PMID 36280611 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a BACKGROUND: Inflammatory adverse events following COVID-19 vaccination are being reported amidst the growing concerns regarding vaccine's immunogenicity and safety, especially in patients with pre-existing inflammatory conditions | ||
| 520 | |a METHODS: Multinational case series of patients diagnosed with an ocular inflammatory event within 14 days following COVID-19 vaccination collected from 40 centres over a 3 month period in 2021 | ||
| 520 | |a RESULTS: Seventy patients presented with ocular inflammatory events within 14 days following COVID-19 vaccination. The mean age was 51 years (range, 19-84 years). The most common events were anterior uveitis (n = 41, 58.6%), followed by posterior uveitis (n = 9, 12.9%) and scleritis (n = 7, 10.0%). The mean time to event was 5 days and 6 days (range, 1-14 days) after the first and second dose of vaccine, respectively. Among all patients, 36 (54.1%) had a previous history of ocular inflammatory event. Most patients (n = 48, 68.6%) were managed with topical corticosteroids. Final vision was not affected in 65 (92.9%), whereas 2 (2.9%) and 3 (4.3%) had reduction in visual acuity reduced by ≤3 lines and > 3 lines, respectively. Reported complications included nummular corneal lesions (n = 1, 1.4%), cystoid macular oedema (n = 2, 2.9%) and macular scarring (n = 2, 2.9%) | ||
| 520 | |a CONCLUSION: Ocular inflammatory events may occur after COVID-19 vaccination. The findings are based on a temporal association that does not prove causality. Even in the possibility of a causal association, most of the events were mild and had a good visual outcome | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Coronavirus disease | |
| 650 | 4 | |a Immunomodulatory | |
| 650 | 4 | |a Ocular inflammation | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Uveitis | |
| 650 | 4 | |a Vaccination | |
| 700 | 1 | |a Brandão-de-Resende, Camilo |e verfasserin |4 aut | |
| 700 | 1 | |a Agrawal, Rupesh |e verfasserin |4 aut | |
| 700 | 1 | |a Pavesio, Carlos |e verfasserin |4 aut | |
| 700 | 0 | |a COVID-19 Vaccination Ocular Inflammatory Events Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Steeples, Laura |e investigator |4 oth | |
| 700 | 1 | |a Balasubramaniam, Balini |e investigator |4 oth | |
| 700 | 1 | |a McCluskey, Peter |e investigator |4 oth | |
| 700 | 1 | |a Pichi, Francesco |e investigator |4 oth | |
| 700 | 1 | |a Agarwal, Aniruddha |e investigator |4 oth | |
| 700 | 1 | |a Herbort, Carl |e investigator |4 oth | |
| 700 | 1 | |a Cimino, Luca |e investigator |4 oth | |
| 700 | 1 | |a Iriqat, Salam |e investigator |4 oth | |
| 700 | 1 | |a Thorne, Jennifer E |e investigator |4 oth | |
| 700 | 1 | |a Echegaray, Jose |e investigator |4 oth | |
| 700 | 1 | |a Babu, Kalpana |e investigator |4 oth | |
| 700 | 1 | |a Bialasiewicz, Alexander Arthur |e investigator |4 oth | |
| 700 | 1 | |a Goldstein, Debra A |e investigator |4 oth | |
| 700 | 1 | |a Ghadiri, Nima |e investigator |4 oth | |
| 700 | 1 | |a Fonollosa Calduch, Alex |e investigator |4 oth | |
| 700 | 1 | |a Andrade, Gabriel Costa de |e investigator |4 oth | |
| 700 | 1 | |a Mahendradas, Padmamalini |e investigator |4 oth | |
| 700 | 1 | |a González-López, Julio J |e investigator |4 oth | |
| 700 | 1 | |a Carreño, Ester |e investigator |4 oth | |
| 700 | 1 | |a Hamam, Rola N |e investigator |4 oth | |
| 700 | 1 | |a Stübiger, Nicole |e investigator |4 oth | |
| 700 | 1 | |a Bodaghi, Bahram |e investigator |4 oth | |
| 700 | 1 | |a Chao, Yu-Jang |e investigator |4 oth | |
| 700 | 1 | |a Takeuchi, Masaru |e investigator |4 oth | |
| 700 | 1 | |a Tay-Kearney, Mei-Ling |e investigator |4 oth | |
| 700 | 1 | |a Portero, Alejandro |e investigator |4 oth | |
| 700 | 1 | |a Keino, Hiroshi |e investigator |4 oth | |
| 700 | 1 | |a Esteban-Ortega, Mar |e investigator |4 oth | |
| 700 | 1 | |a Przeździecka-Dołyk, Joanna |e investigator |4 oth | |
| 700 | 1 | |a Radosavljević, Aleksandra |e investigator |4 oth | |
| 700 | 1 | |a Paredes, Ian |e investigator |4 oth | |
| 700 | 1 | |a Agrawal, Rupesh |e investigator |4 oth | |
| 700 | 1 | |a Ling, Ho Su |e investigator |4 oth | |
| 700 | 1 | |a Kiong, Wei |e investigator |4 oth | |
| 700 | 1 | |a Tien, Melissa |e investigator |4 oth | |
| 700 | 1 | |a Ng, Xin Le |e investigator |4 oth | |
| 700 | 1 | |a Pavesio, Carlos |e investigator |4 oth | |
| 700 | 1 | |a Testi, Ilaria |e investigator |4 oth | |
| 700 | 1 | |a Chee, Soon Phaik |e investigator |4 oth | |
| 700 | 1 | |a Siak, Jay |e investigator |4 oth | |
| 700 | 1 | |a Hernanz-Rodriguez, Ines |e investigator |4 oth | |
| 700 | 1 | |a Menezo, Victor |e investigator |4 oth | |
| 700 | 1 | |a Tappeiner, Christoph |e investigator |4 oth | |
| 700 | 1 | |a Cruz, Franz Marie |e investigator |4 oth | |
| 700 | 1 | |a Addison, Peter |e investigator |4 oth | |
| 700 | 1 | |a Kuijpers, Robert |e investigator |4 oth | |
| 700 | 1 | |a Vasconcelos-Santos, Daniel Vitor |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of ophthalmic inflammation and infection |d 2010 |g 12(2022), 1 vom: 04. Jan., Seite 4 |w (DE-627)NLM20730887X |x 1869-5760 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:1 |g day:04 |g month:01 |g pages:4 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12348-021-00275-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 1 |b 04 |c 01 |h 4 | ||